Welcome to our dedicated page for Thermo Fishr Sci SEC filings (Ticker: TMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Thermo Fisher Scientific Inc. (NYSE: TMO) files a wide range of documents with the U.S. Securities and Exchange Commission, and this page aggregates those SEC filings for investors tracking TMO. The company’s common stock and multiple series of senior notes are listed on the New York Stock Exchange, and its filings describe the terms, rankings and covenants of these securities, as well as material events affecting the business.
Recent Form 8‑K filings illustrate the types of information Thermo Fisher discloses. Several 8‑Ks detail public offerings of senior notes in U.S. dollars and euros, including maturities, interest payment schedules, redemption provisions, change‑of‑control protections and the use of proceeds for general corporate purposes such as acquisitions, debt repayment or refinancing, working capital, capital expenditures or equity repurchases. Other 8‑Ks report the completion of the acquisition of Solventum Corporation’s purification and filtration business and the signing of a definitive agreement to acquire Clario Holdings, Inc.
Thermo Fisher also uses 8‑K filings to communicate quarterly financial results, leadership transitions and organizational changes. For example, filings describe announcements of financial results for specific fiscal quarters, the planned retirement of the Senior Vice President and Chief Financial Officer and the appointment of a successor, and updates to the organizational structure and leadership team, including changes in executive roles.
On Stock Titan’s SEC filings page for TMO, users can access these current reports alongside other registered securities information, and benefit from AI‑powered summaries that explain key terms, highlight significant covenants, and clarify how new debt offerings, acquisitions, leadership changes or other material events may affect Thermo Fisher Scientific’s capital structure and corporate profile.
Thermo Fisher Scientific’s Q2-25 results show modest growth, lower margins and weaker cash conversion.
Total revenue rose 3% YoY to $10.86 b; product sales +1%, services +5%. Operating income edged up 1% to $1.83 b but margin slipped 40 bp to 16.9% after $82 m of restructuring charges. Net income attributable to TMO increased 4.5% to $1.62 b; diluted EPS climbed 6% to $4.28.
For six months, revenue reached $21.22 b (+1.6%) and EPS $8.26 (+10%). Operating cash flow fell 34% to $2.12 b as inventories (+12%) and receivables (+5%) expanded. The company repurchased $2.0 b of shares, paid $311 m in dividends and issued $2.84 b of new debt, lifting total borrowings to $35.3 b (par) while cash rose to $4.58 b.
Segment revenue YoY: Life Sciences Solutions +6% ($2.50 b); Analytical Instruments −3% ($1.73 b); Specialty Diagnostics +1% ($1.13 b); Laboratory Products & Biopharma Services +4% ($6.00 b). Growth came from North America (+3%) and Europe (+6%); Asia-Pacific declined 3%.
The effective tax rate dropped to 5.6% YTD (vs 12.2%) thanks to a $153 m deferred-tax benefit on intra-entity transfers. Management expects another ~$140 m of restructuring, mainly in Laboratory Products.
Investor focus: steady EPS aided by tax gains, soft operating margin, cash-flow pressure, and higher leverage partially offset by strong liquidity.
Thermo Fisher Scientific (TMO) — Form 4 insider transaction
Executive Vice President Gianluca Pettiti reported the sale of 400 common shares on 07/25/2025 at $479.98 per share, generating roughly $0.19 million in proceeds. The trade was executed under a Rule 10b5-1 plan that Pettiti adopted on 02/10/2025, indicating it was pre-scheduled and not based on current market conditions.
Post-transaction, the executive directly owns 22,366.925 shares. No derivative securities were bought or sold and no indirect holdings were reported. The filing discloses no additional company fundamentals or other insider activity.
- Transaction size is modest relative to Pettiti’s remaining stake, suggesting continued alignment with shareholders.
- No impact on share count or control structure; purely a personal liquidity event.
On 25 Jul 2025, Thermo Fisher Scientific, Inc. (TMO) filed a Form 144 indicating that Gianluca Pettiti intends to sell up to 400 common shares through Fidelity Brokerage Services on the NYSE. The proposed sale, valued at $191,992, equals roughly 0.0001 % of the 377,493,912 shares outstanding, implying negligible dilution or market impact.
The stock to be sold stems from two restricted-stock vestings received as compensation (235 shares on 23 Aug 2024 and 165 shares on 28 Aug 2024). Pettiti has already sold 700 shares over the past three months, generating gross proceeds of $293,423.
No Rule 10b5-1 trading-plan date is disclosed. The filer certifies possession of no undisclosed adverse information, and the notice contains no financial results, guidance, or operational updates. Overall, the filing reflects a routine, small-scale insider transaction with limited investment significance.